Strategic Partnerships Depixus has established collaboration with a major global pharma player (Daiichi Sankyo) to apply MAGNA technology to RNA-targeted drug discovery, signaling a clear channel for enterprise collaborations and funded research programs.

Product Momentum The launch of MAGNA One positions Depixus to offer scalable, single-molecule interaction analysis at scale, opening up opportunities to sell to laboratories and CROs seeking advanced interactomics capabilities.

Commercialization Drive Recent appointment of a Chief Commercial Officer indicates a sharpened go-to-market strategy and a focus on accelerating sales, partner channels, and large account close plans.

R&D to Revenue Awards from SLAS Ignite reflect external validation of innovative MAGNA technology, helping to elevate credibility with potential customers and funders, aiding outreach to research institutions and biotechs.

Early Access Programs Technology access program and initial instrument placements suggest a pipeline of early adopters; target academic labs and biotech startups as entry points for pilots that can expand into larger multi-site deployments.